ArticleCancer research2007

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Francesco Dieli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.